Literature DB >> 20195693

Design, synthesis, and evaluation of cyclofenil derivatives for potential SPECT imaging agents.

Hua Zhu1, Liliang Huang, Yuanqing Zhang, Xiaoping Xu, Yanhong Sun, Yu-Mei Shen.   

Abstract

To develop technetium- and rhenium-labeled nonsteroidal estrogen imaging agents for estrogen receptor (ER) positive breast tumors, two groups of rhenium and technetium cyclofenil derivatives were synthesized and characterized. The binding affinities of the rhenium complexes for ERs were determined. The tricarbonyl rhenium complex showed the highest binding affinity for ERs (81.2 for ERbeta, 16.5 for ERalpha). Tricarbonyl technetium cyclofenil complexes were obtained in high radiochemical purity and radiochemical yields. The results of studies of their octanol/water partition and in vitro stability are presented. These results demonstrate that these radiolabeled cyclofenil derivatives may be considered as potential breast cancer imaging agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195693     DOI: 10.1007/s00775-010-0627-0

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  41 in total

1.  Comparative QSAR analysis of estrogen receptor ligands.

Authors:  H Gao; J A Katzenellenbogen; R Garg; C Hansch
Journal:  Chem Rev       Date:  1999-03-10       Impact factor: 60.622

Review 2.  Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.

Authors:  S L Silfen; A V Ciaccia; H U Bryant
Journal:  Climacteric       Date:  1999-12       Impact factor: 3.005

3.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Photoaffinity labels for estrogen binding proteins of rat uterus.

Authors:  J A Katzenellenbogen; H J Johnson; H N Myers
Journal:  Biochemistry       Date:  1973-10-09       Impact factor: 3.162

5.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.

Authors:  P Roger; M E Sahla; S Mäkelä; J A Gustafsson; P Baldet; H Rochefort
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

6.  18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.

Authors:  Yann Seimbille; Jacques Rousseau; François Bénard; Catherine Morin; Hasrat Ali; George Avvakumov; Geoffrey L Hammond; Johan E van Lier
Journal:  Steroids       Date:  2002-08       Impact factor: 2.668

Review 7.  Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.

Authors:  Mark Bartholomä; John Valliant; Kevin P Maresca; John Babich; Jon Zubieta
Journal:  Chem Commun (Camb)       Date:  2008-12-01       Impact factor: 6.222

8.  Synthesis, estrogen receptor binding, and tissue distribution of a new iodovinylestradiol derivative (17alpha,20E)-21-[123I]Iodo-11beta-nitrato-19-norp regna-1,3,5 (10),20-tetraene-3,17-diol (E-[123I]NIVE).

Authors:  L J Rijks; J C van den Bos; P A van Doremalen; G J Boer; K de Bruin; T Doornbos; J A Vekemans; M A Posthumus; A G Janssen; E A van Royen
Journal:  Nucl Med Biol       Date:  1998-05       Impact factor: 2.408

9.  16 alpha-[77Br]bromoestradiol-17 beta: a high specific-activity, gamma-emitting tracer with uptake in rat uterus and uterus and induced mammary tumors.

Authors:  J A Katzenellenbogen; S G Senderoff; K D McElvany; H A O'Brien; M J Welch
Journal:  J Nucl Med       Date:  1981-01       Impact factor: 10.057

10.  Oestrogen receptor beta: how should we measure this?

Authors:  V Speirs; P J Carder; M R J Lansdown
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.